Comprehensive Cancer Centres and the war on cancer

Nature Reviews Cancer

Volumn 1, Issue 3, 2001, Pages 240-245

  Nathan, David ^a   Benz Jr , Edward J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CENTER; ECONOMICS; FINANCIAL MANAGEMENT; FORECASTING; HEALTH CARE ORGANIZATION; HISTORY; HUMAN; NEOPLASM; ORGANIZATION AND MANAGEMENT; RESEARCH; REVIEW; UNITED STATES;

CANCER CARE FACILITIES; FORECASTING; HISTORY, 20TH CENTURY; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; RESEARCH; RESEARCH SUPPORT; UNITED STATES;

EID: 0035756720     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/35106102     Document Type: Article

References (40)

1. Walter, W. A., Saunders, J. P. & Putney, H. D. Origins of the Cancer Center Program of the National Cancer Institute, Association of American Cancer Institutes Newsletter (June 1985).
2. Walter, W. A. & King, T. J. The Cancer Centers Program. J. Natl Cancer Inst. 59, 645-649 (1977).
3. Chronological History of the Cancer Centers Program: Prepared for the Committee to Study the Cancer Centers Program of the National Cancer Institute. (Institute of Medicine National Academy of Sciences, Washington D. C., 1989).
4. Science, the Endless Frontier: a report to the President by V. Bush, Director of the Office of Scientific Research and Development, printed by the US Government Printing Office, Washington, DC, 1945.
5. Yarbro J. W. & Newell G. R. Cancer Centers: their relationship to the academic community. J. Med. Educ. 51, 487-495 (1976).
6. Freireich, E. J., Gehan, E., Sulman, D., Boggs, D. R. & Frei, E. The effect of chemotherapy on acute leukemia in the human. J. Chronic Dis. 14, 593-608 (1961).
7. DeVita, V. T. Jr, Serpick, A. A. & Carbone, P. P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann. Intern. Med. 73, 881-895 (1970).
8. DeVita, V. T. Jr et al. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Results with combination chemotherapy. Lancet 1, 248-250 (1975).
9. Bagley, C. M., DeVita, V. T. Jr, Berard, C. W. & Canellos, G. P. Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann. Intern. Med. 76, 227-234 (1972).
10. Canellos, G. P. et al. Combination chemotherapy for advanced breast cancer: response and effect of survival. Ann. Intern. Med. 84, 389-392 (1976).
11. A Stronger Cancer Centers Program: A report of a committee of the Institute of Medicine Division of Health Care Services. (National Academy Press, Washington D. C., 1989).
12. Simone, J. V. et al. Renewing the Cancer Centers Program of the National Cancer Institute: Report of the Cancer Centers Program Review Group to the Director of NCI (October 2, 1996).
13. Blattner, W. A. Human retroviruses: their role in cancer. Proc. Assoc. Am. Physicians 111, 563-572 (1999).
14. Pagano, J. S. Epstein-Barr virus: the first human tumor virus and its role in cancer. Proc. Assoc. Am. Physicians 111, 573-580 (1999).
15. Lichtenstein, P. et al. Environmental and heritable factors in the causation of cancer. N. Engl. J. Med. 343, 78-85 (2000).
16. Delves, P. J. & Riott, I. M. The immune system. N. Engl. J. Med. 343, 37-49, 108-117 (2000).
17. Bal, D. G. Cancer Statistics 2001: quo vadis or whither goest thou?. CA Cancer J. Clin. 51, 11-14 (2001).
18. Greenlee, R. T., Hill-Harmon, M. B., Murray, T. & Thun, M. Cancer Statistics 2001. CA Cancer J. Clin. 51, 15-38 (2001).
19. Michaud, D. S. et al. Physical activity, obesity, height, and the risk of pancreatic cancer. J. Am. Med. Assoc. 286, 921-929 (2001).
20. Joffe, M. M., Byrne, C. & Colditz, G. A. Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias. Epidemiology 12, 429-438 (2001).
21. Zhang, S. M. et al. Vitamin supplement use and the risk of non-Hodgkin's lymphoma among women and men. Am. J. Epidemiol. 153, 1056-1063 (2001).
22. Greenberg, E. R. et al. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. N. Engl. J. Med. 323, 789-795 (1990).
23. Janne, P. A. & Mayer, R. J. Chemoprevention of colorectal cancer. N. Engl. J. Med. 342, 1960-1968 (2000).
24. Moertel, C. G. et al. 5-FU plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann. Intern. Med. 122, 321-326 (1995).
25. Hong W. K. et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. W. Engl. J. Med. 323, 795-801 (1990).
26. Porter J. D. Colorectal cancer: molecules and populations. J. Natl Cancer Inst. 91, 916-932 (1999).
27. Brett, D. et al. A rapid bioinfomatic method identifies novel genes with direct clinical relevance to colon cancer. Oncogene 20, 4581-4585 (2001).
28. Dong, S. M. et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J. Natl Cancer Inst. 93, 858-865 (2001).
29. Anon. Much ado about data. Nature Med. 7, 751 (2001).
30. Groopman, J. The Thirty Years War: have we been fighting cancer the wrong way? The New Yorker 52 (June 4, 2001).
31. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
32. Druker, B. J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042 (2001).
33. Goldman, J. M. & Melo, J. V. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1084-1086 (2001).
34. Joensuu, H. et al. Effect of the tyrosine kinase inhibitor STI-571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 344, 1052-1051 (2001).
35. Thomas, E. D. A history of haemopoietic cell transplantation. Br. J. Haematol. 105, 330-339 (1999).
36. Silverman, L. B. et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 97, 1211-1218 (2001).
37. Pegram, M. D., Konecny, G. & Slamon, D. J. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat. Res. 103, 57-75 (2000).
38. Moore, M. A. The clinical use of colony stimulating factors. Annu. Rev. Immunol. 9, 159-191 (1991).
39. Cho, Y., Gorina, S., Jeffrey, P. D. & Pavletich, N. P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265, 346-355 (1994).
40. Bhattacharjee, A. et al. Classification of human lung carcinomas by mRNA expression analysis. Proc. Natl Acad. Sci. (in the press).